Delaware
(State or Other Jurisdiction of Incorporation)
|
001-34079
(Commission File Number)
|
11-3516358
(I.R.S. Employer Identification No.)
|
15245 Shady Grove Road, Suite 455
Rockville, MD
|
20850
|
(Address of principal executive offices)
|
(Zip Code)
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.02. |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
Item 5.07. |
Submission of Matters to a Vote of Security Holders.
|
Director
|
For
|
Withheld
|
Broker Non-Votes
|
|||
Chang H. Ahn
|
96,338,097
|
8,133,172
|
78,520,392
|
|||
Charles Beever
|
94,458,425
|
10,012,844
|
78,520,392
|
|||
Peter Brandt
|
95,807,793
|
8,663,476
|
78,520,392
|
|||
Mark Carthy
|
94,717,638
|
9,753,631
|
78,520,392
|
|||
Kwang Soo Cheong
|
94,610,217
|
9,861,052
|
78,520,392
|
|||
Richard J. Rodgers
|
94,743,672
|
9,727,597
|
78,520,392
|
|||
Peter Suzdak
|
94,774,370
|
9,696,899
|
78,520,392
|
For
|
Against
|
Abstain
|
||
168,708,302
|
4,347,995
|
9,935,364
|
For
|
Against
|
Abstain
|
||
82,573,930
|
12,908,813
|
8,988,524
|
Every one year
|
Every two years
|
Every three years
|
Abstain
|
|||
31,598,028
|
4,387,045
|
57,185,030
|
11,301,164
|
For
|
Against
|
Abstain
|
||
69,888,918
|
27,581,379
|
7,000,970
|
For
|
Against
|
Abstain
|
||
124,909,518
|
53,287,821
|
4,794,318
|
For
|
Against
|
Abstain
|
||
145,973,361
|
29,481,505
|
7,536,788
|
Item 8.01 |
Other Events.
|
Item 9.01 |
Financial Statements and Exhibits.
|
(d) |
Exhibits.
|
Exhibit No.
|
Description
|
10.1
|
First Amendment to the Rexahn Pharmaceuticals, Inc. 2013 Stock Option Plan, as Amended and Restated as of June 9, 2016.
|
99.1
|
Rexahn Pharmaceuticals, Inc. press release dated April 13, 2017, announcing reverse stock split and corresponding authorized share reduction.
|
REXAHN PHARMACEUTICALS, INC.
|
||
Dated: April 13, 2017
|
||
/s/ Peter Suzdak
|
||
Peter Suzdak
|
||
Chief Executive Officer
|
Exhibit No.
|
Description
|
First Amendment to the Rexahn Pharmaceuticals, Inc. 2013 Stock Option Plan, as Amended and Restated as of June 9, 2016.
|
|
Rexahn Pharmaceuticals, Inc. press release dated April 13, 2017, announcing reverse stock split and corresponding authorized share reduction.
|
1. |
Section 4 of the Plan is hereby deleted and replaced in its entirety with the following:
|
4. |
Maximum Shares Available for the Plan
|
2. |
Except as amended above, the Plan shall remain in full force and effect.
|
REXAHN PHARMACEUTICALS, INC.
|
||
By: |
/s/ Tae Heum Jeong
|
Name: |
Tae Heum Jeong
|
|
Title: |
Chief Financial Officer and Secretary
|